Clinical Trials
Chromatin Regulator Mutations Associate With Elevated TMB and Prolonged Survival in Melanoma
Gjorgjievska et alPigment cell & melanoma research

Melanoma typically exhibits high tumor mutational burden (TMB) driven predominantly by ultraviolet-induced DNA damage, but the genomic drivers of TMB variability beyond canonical mismatch repair (MMR) and POLE/POLD1 mutations remain unclear. To assess whether alterations in chromatin regulators (CRs) affect genome stability and mutational burden, researchers evaluated melanoma cohorts from the MSK-ICI, TCGA, MSK-Met, DFCI, and UCLA datasets.
TMB was compared between CR-mutant and CR-wild-type tumors and across overall cohorts, alongside gene-level evaluations of individual CRs and the relationship between mutation count and TMB. Overall survival (OS) among patients treated with immune checkpoint inhibitors (ICIs) was evaluated via Kaplan-Meier and Cox models, using TCGA as a non-ICI-treated comparator.
Across datasets, CR-mutant melanomas consistently exhibited significantly higher TMB than CR-wild-type tumors, with multiple individual CR alterations linked to elevated TMB levels comparable to MMR- or POLE/POLD1-mutant tumors. Furthermore, multiple CR alterations showed a positive linear relationship with TMB. Among ICI-treated cohorts, CR-mutant tumors had significantly longer OS, whereas this survival association was not observed in non-ICI-treated cases. The authors concluded that CR mutations define a melanoma subset with elevated TMB and improved ICI response, suggesting they warrant prospective validation as predictive biomarkers.
Key Takeaways
- Patients with chromatin regulator-mutant melanomas had significantly longer overall survival in immune checkpoint inhibitor-treated cohorts, a survival link not observed in non-ICI-treated cases.
- Chromatin regulator-mutant melanomas consistently exhibited significantly higher tumor mutational burden than wild-type tumors across datasets, showing elevated mutational loads comparable to mismatch repair- or POLE/POLD1-mutant tumors.
Read the original sourcePigment cell & melanoma research
